Andrew Steele
Optometrist · Crestwood, KYNPI 1942685169
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,003 of the $9,243 with a category attached, or 86.6%. It is spread thinly across 21 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,573 and has fallen 56.6% since, to $1,118 in 2025. Among optometrist clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $31.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biotissue Holdings Inc.$2K
- Alcon$940
- Amgen$733
- Sun Pharmaceutical Industries Inc.$674
- Bausch & Lomb, A Division Of Bausch Health US, LLC$537
- plus $3K from 15 others
What the payments were for
- Travel & lodging$1,10012%
- Food & beverage$8,00387%
- Education$1402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $1,915 |
| Biotissue Holdings Inc. | 12 | $1,553 |
| Alcon | 27 | $940 |
| Amgen(2 entities) | 32 | $733 |
| Sun Pharmaceutical Industries Inc. | 24 | $674 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 27 | $537 |
| Mallinckrodt Hospital Products Inc. | 11 | $485 |
| ANI Pharmaceuticals, Inc. | 10 | $470 |
| Aerie Pharmaceuticals, Inc. | 10 | $326 |
| Tarsus Pharmaceuticals, Inc. | 9 | $325 |
| Bausch & Lomb Americas Inc. | 7 | $292 |
| Novartis | 18 | $279 |
| Oyster Point Pharma, Inc. | 7 | $252 |
| Kala Pharmaceuticals, Inc. | 6 | $180 |
| Dompe US, Inc. | 4 | $85 |
| Eyevance Pharmaceuticals LLC | 3 | $42 |
| Ocular Therapeutix, Inc. | 3 | $42 |
| Harrow Eye, LLC | 2 | $36 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| Ivantis, Inc | 2 | $27 |
| Sight Sciences, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$1,218
- AmnioGraft$1,218
- CEQUA$477
- PURIFIED CORTROPHIN GEL$299
- XELPROS$269
- Rhopressa$250
- XEN GLAUCOMA TREATMENT SYSTEM$244
- TEPEZZA$243
- Rocklatan$230
- Voyager DSLT$150
- LUMIGAN$134
- RESTASIS$132
- SIMBRINZA$127
- ReSTOR$125
- TYRVAYA$125
- XEN$124
- BROMSITE$121
- VUITY$118
- EYSUVIS$116
- Clareon$109
How this compares
$9,243 in reported general payments places this provider in the 95th percentile of 712 optometrist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 184 | $66,292 |
| RestasisCyclosporine | 53 | $55,569 |
| VyzultaLatanoprostene Bunod | 132 | $42,833 |
| RocklatanNetarsudil Mesylat/Latanoprost | 91 | $35,802 |
| CombiganBrimonidine Tartrate/Timolol | 98 | $29,772 |
| CequaCyclosporine | 21 | $21,820 |
| Cyclosporine | 23 | $21,787 |
| Fluorometholone | 263 | $19,857 |
| Prednisolone Acetate | 469 | $17,064 |
| RhopressaNetarsudil Mesylate | 19 | $9,759 |
| Alphagan PBrimonidine Tartrate | 26 | $7,468 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 53 | $6,651 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 31 | $6,078 |
| Latanoprost | 610 | $5,241 |
| Bromfenac Sodium | 21 | $5,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,915 | $159,100361 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $326 | $45,561110 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $292 | $42,833132 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $674 | $21,82021 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $537 | $6,07927 claims |
| AlconSimbrinza | $940 | $6,07831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 optometrist providers in Kentucky.
Other optometrist in Crestwood
- Paul KarpeckiLexington$3.6M
- Bilal AhmadLexington$150K
- Clay MattsonNicholasville$93K
- Ben LeonardCalvert City$75K
- Lee PeplinskiLouisville$74K
- Austin LifferthLouisville$72K
- Christopher KucLexington$52K
- Kristine Kerestan GarbigWilder$51K
- Renee ReederPikeville$27K
- Karoline MunsonFrankfort$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.